Compare LOOP & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | XBIT |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.2M | 74.4M |
| IPO Year | 2010 | 2015 |
| Metric | LOOP | XBIT |
|---|---|---|
| Price | $1.00 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.7K | 26.1K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.88 | $2.09 |
| 52 Week High | $1.99 | $3.61 |
| Indicator | LOOP | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 24.10 | 39.19 |
| Support Level | $0.90 | $2.35 |
| Resistance Level | $1.42 | $2.41 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 5.02 | 13.79 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.